Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.

Chen, Jin; Stringer, Rowan; Shah, Bharti; Gu, Jessie; Zhang, Yiming; Hackling, Melissa; Prince, William; Woessner, Ralph

Chen, Jin; Stringer, Rowan; Shah, Bharti; Gu, Jessie; Zhang, Yiming; Hackling, Melissa; Prince, William; Woessner, Ralph.

Afiliação

Chen J; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Stringer R; Novartis Institutes for BioMedical Research, PK Sciences, Basel, Switzerland.
Shah B; Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA.
Gu J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Zhang Y; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Hackling M; Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA.
Prince W; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Woessner R; Novartis Institutes for BioMedical Research, PK Sciences, Basel, Switzerland.

Clin Pharmacol Drug Dev ; 11(11): 1253-1263, 2022 11.

Article em En | MEDLINE | ID: mdl-35962468

Assuntos

Citocromo P-450 CYP3A; Itraconazol; Humanos; Citocromo P-450 CYP3A/metabolismo; Inibidores do Citocromo P-450 CYP3A/farmacologia; Interações Medicamentosas; Voluntários Saudáveis; Rifampina

Palavras-chave

cytochrome P450; drug-drug interactions; nonalcoholic steatohepatitis; pharmacokinetics; tropifexor; uridine 5'-diphosphoglucuronosyltransferases

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Itraconazol / Citocromo P-450 CYP3A Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google